PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12808176-1	2003	BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI.	Heparin	12-19	tissue factor pathway inhibitor	Homo sapiens	90-121	
12808176-1	2003	BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI.	Heparin	12-19	tissue factor pathway inhibitor	Homo sapiens	123-127	
12808176-1	2003	BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI.	Heparin	12-19	tissue factor pathway inhibitor	Homo sapiens	219-223	
12808176-1	2003	BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI.	Heparin	183-190	tissue factor pathway inhibitor	Homo sapiens	90-121	
12808176-1	2003	BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI.	Heparin	183-190	tissue factor pathway inhibitor	Homo sapiens	123-127	
12808176-1	2003	BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI.	Heparin	183-190	tissue factor pathway inhibitor	Homo sapiens	219-223	
12808176-8	2003	In patients switched to UFH, TF levels remained unchanged compared with pre-randomization values, TFPI increased at each interval of HD sessions (all P<0.035) and PF 1+2 increased pre-dialysis (P=0.015).	Heparin	24-27	tissue factor pathway inhibitor	Homo sapiens	98-102	
12808176-10	2003	In contrast, baseline TFPI and its 10-min rise correlated inversely with the UFH loading dose (both P<0.040).	Heparin	77-80	tissue factor pathway inhibitor	Homo sapiens	22-26	
12808176-12	2003	CONCLUSIONS: Depletion of heparin-releasable stores of TFPI is an untoward effect of repeated anticoagulation during maintenance HD therapy.	Heparin	26-33	tissue factor pathway inhibitor	Homo sapiens	55-59	
12808176-13	2003	The traditional UFH regimen is more prothrombotic than single enoxaparin injections, with high loading doses of UFH being involved in TFPI exhaustion and subsequent hypercoagulability.	Heparin	112-115	tissue factor pathway inhibitor	Homo sapiens	134-138